-

01:57:50 PM

LLY Stock News

LLY - Lilly(Eli) & Co

10/02/23 6:45 AM

NYSE : LLY

U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer

Eli Lilly and Company announced that the U.S. Food and Drug Administration has issued a complete response letter for the lebrikizumab biologic license application for the treatment of moderate-to-severe atopic...

RHEA-AI

neutral

09/22/23 8:33 AM

NYSE : LLY

fda approval

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease Jardiance ® 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD, as established in the EMPA-KIDNEY phase III trial EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to...

RHEA-AI

neutral

08/22/23 7:45 AM

NYSE : LLY

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Eli Lilly and Company today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection- mutant medullary thyroid...

RHEA-AI

negative

08/14/23 9:09 AM

NYSE : LLY

acquisition

Lilly Completes Acquisition of Versanis Bio

Eli Lilly and Company today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2 b study alone and in combination with semaglutide in adults living with overweight or...

RHEA-AI

neutral

08/14/23 7:25 AM

NYSE, Nasdaq : LLY, SGTX

acquisition

Lilly Completes Acquisition of Sigilon Therapeutics

Eli Lilly and Company today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc.. As previously announced, Lilly and Sigilon entered into a Merger Agreement dated as of June 28, 2023, and pursuant thereto, on July 13, 2023, Lilly and a wholly owned subsidiary commenced a tender offer to...

RHEA-AI

neutral

08/09/23 9:02 AM

NYSE, Nasdaq : LLY, DICE

acquisition

Lilly Completes Acquisition of DICE Therapeutics

Eli Lilly and Company today announced the successful completion of its acquisition of DICE Therapeutics, Inc.. The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in...

RHEA-AI

neutral

08/08/23 6:45 AM

NYSE : LLY

earnings

Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements

Excluding revenue from Baqsimi, and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%. Pipeline progress included positive results in the Phase 3 TRAILBLAZER-ALZ 2 study and the submissions of donanemab for traditional approval to the FDA and EMA; the completed submission of tirzepatide in chronic weight management to the FDA and positive...

RHEA-AI

neutral

08/04/23 7:45 AM

NYSE : LLY

Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed– with or without pembrolizumab– as an initial treatment for patients with rearranged during transfection fusion-positive advanced or metastatic non-small...

RHEA-AI

negative

07/27/23 6:48 AM

NYSE : LLY

Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies

Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry over 84 weeks. Participants in SURMOUNT-4 achieved 21.1% weight loss during a 36- week tirzepatide lead-in period and an additional 6.7% weight loss during a...

RHEA-AI

neutral

07/25/23 10:00 AM

NYSE : LLY

earnings

Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement

Eli Lilly and Company will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m.

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next